Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Caplin Point LaboratoriesNSE:CAPLIPOINT -1.56%88 5-Year Yield-on-Cost % is 2.27 as of Jul. 22, 2026, which is 30% below its 10-year median of 3.24. GuruFocus rates NSE:CAPLIPOINT with a GF Score™ of 88/100 and a GF Value™ of ₹2,093.16 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 513 Drug Manufacturers companies, Caplin Point Laboratories ranks better than 50.68% on this metric.
The historical rank and industry rank for Caplin Point Laboratories's 5-Year Yield-on-Cost % or its related term are showing as below:
NSE:CAPLIPOINT'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.52 Med: 3.24 Max: 14.17
Current: 2.27
During the past 13 years, Caplin Point Laboratories's highest Yield on Cost was 14.17. The lowest was 0.52. And the median was 3.24.
NSE:CAPLIPOINT's 5-Year Yield-on-Cost % is ranked better than 50.68% of 513
companies
in the Drug Manufacturers industry
Industry Median: 2.29
vs NSE:CAPLIPOINT: 2.27
Caplin Point Laboratories (NSE:CAPLIPOINT) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Caplin Point Laboratories 5-Year Yield-on-Cost % Related Terms
NSE:CAPLIPOINT vs ZTS, UTHR: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Caplin Point Laboratories's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caplin Point Laboratories 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Caplin Point Laboratories's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Caplin Point Laboratories's 5-Year Yield-on-Cost % falls into.
Caplin Point Laboratories 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Caplin Point Laboratories (NSE:CAPLIPOINT) has a 5-Year Yield-on-Cost % of 2.27 as of Jul. 22, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Caplin Point Laboratories and its competitors. This is 30% below median its historical median of 3.24. Over the past decade, Caplin Point Laboratories' 5-Year Yield-on-Cost % has ranged from 0.52 to 14.17. According to the industry distribution chart, Caplin Point Laboratories ranks #253 out of 513 companies in the Drug Manufacturers industry, placing it in the top 49.3%.
Is Caplin Point Laboratories' 5-Year Yield-on-Cost % too high?
Caplin Point Laboratories' current 5-Year Yield-on-Cost % of 2.27 is 30% below median its 10-year median of 3.24. Over the past 10 years, this metric has ranged from a low of 0.52 to a high of 14.17. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.29. Caplin Point Laboratories' value of 2.27 is 0.9% below this industry median. Based on the distribution chart, Caplin Point Laboratories ranks #253 out of 513 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Caplin Point Laboratories has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Caplin Point Laboratories' 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Caplin Point Laboratories ranks #253 out of 513 companies for 5-Year Yield-on-Cost %. This puts Caplin Point Laboratories in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.29. Caplin Point Laboratories' value of 2.27 is 0.9% below this benchmark. Historically, Caplin Point Laboratories' own 5-Year Yield-on-Cost % has ranged from 0.52 to 14.17 over the past decade. While the company's 10-year median is 3.24 vs. the industry median of 2.29, Caplin Point Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.29, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Caplin Point Laboratories's current 5-Year Yield-on-Cost % of 2.27 is 0.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Caplin Point Laboratories and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caplin Point Laboratories's current 5-Year Yield-on-Cost % is 2.27, which is 30% below median its own 10-year median of 3.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caplin Point Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Caplin Point Laboratories (NSE:CAPLIPOINT) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,093.16, compared to a current price of ₹2,608.00 — trading 24.6% above its estimated fair value. The current 5-Year Yield-on-Cost % is 2.27, which is 30% below median its 10-year median of 3.24 and 0.9% below the Drug Manufacturers industry median of 2.29. Caplin Point Laboratories' overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Caplin Point Laboratories (NSE:CAPLIPOINT), the current 5-Year Yield-on-Cost % is 2.27 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Caplin Point Laboratories (NSE:CAPLIPOINT) Overvalued in 2026?
Based on GuruFocus' analysis, Caplin Point Laboratories stock appears to be overvalued.
The current stock price of ₹2,608.00 is trading 24.6% above its estimated GF Value™ of ₹2,093.16.
GuruFocus considers Caplin Point Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:CAPLIPOINT:
5-Year Yield-on-Cost %: 2.27 (30% below median its 10-year median of 3.24)
GF Value™: ₹2,093.16 vs. price of ₹2,608.00 (24.6% above fair value)
Industry Position: 0.9% below the Drug Manufacturers median (#253 of 513)
No single metric tells the full story. See the NSE:CAPLIPOINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Caplin Point Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical products. The company's key products include tablets, capsules, injections (liquid and lyophilized, prefilled syringes), ophthalmic solutions, liquid orals, soft gel capsules, ointments, creams, gels, powders for injections, suppositories, ovules, pre-mix bag formulations, inhalers, sprays, and IV infusions. It also provides pharmaceutical formulations in specialized injectable dosage forms and Ophthalmic drops.
88GF Score
Get the complete analysis for NSE:CAPLIPOINT
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CAPLIPOINT has been successfully added to your 
